The stomach in health and disease

Gut

Volumn 64, Issue 10, 2015, Pages 1650-1668

  Hunt, R H ^a   Camilleri, M ^b   Crowe, S E ^c   El Omar, E M ^d   Fox, J G ^e   Kuipers, E J ^f   Malfertheiner, P ^g   McColl, K E L ^h   Pritchard, D M ⁱ   Rugge, M ^j   Sonnenberg, A ^k   Sugano, K ^l   Tack, J ^m  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j UNIVERSITY OF PADOVA   (Italy)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l JICHI MEDICAL UNIVERSITY   (Japan)

^m UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN I; PEPSINOGEN II; PROTON PUMP INHIBITOR;

ARTICLE; BACTERIAL COLONIZATION; DUODENUM ULCER; DYSPEPSIA; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; FOOD INTAKE; GASTRIC ACCOMODATION; GASTRIC DYSMOTILITY; GASTRIC SENSITIVITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEALTH STATUS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; HUNGER; IMMUNE STATUS; INTESTINE FLORA; INVASIVE PROCEDURE; MECHANORECEPTOR; NON INVASIVE MEASUREMENT; NONHUMAN; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SATIETY; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH DISEASE; STOMACH FUNCTION; STOMACH MOTILITY; STOMACH PARESIS; STOMACH PRESSURE; STOMACH ULCER; ANATOMY AND HISTOLOGY; GASTRIC MUCOSA; METABOLISM; PHYSIOLOGY; STOMACH; STOMACH DISEASES;

GASTRIC MUCOSA; HUMANS; STOMACH; STOMACH DISEASES;

EID: 84941341036     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307595     Document Type: Article

References (224)

1. Modlin IM From prout to the proton pump. Konstanz: Schnetzor-Verlag GmbH, 1995. ISBN 3-87018-118-4
2. Paracelsus AP Volumen Medicinae Paramirum (c. 1520). In Goodrick-Clarke N, Ed. Paracelsus: essential readings. Berkley, California: North Atlantic Books, 1999:45.
3. Pagel W. Joan Baptista Van Helmont: reformer of science and medicine. Cambridge University Press, 2002:136. Quoting Van Helmont A sede animae ad morbus.
4. Reaumur RAF. Sur la digestion des oiseaux. In: Memoires de l'Academie Royale des Sciences. Paris: L'Imprimerie Royale, 1752:266-308.
5. Spallanzani L. Dissertazione de fisca animale e vegetabile. Modena: Societa Tipografica, 1780.
6. Prout W. On the nature of acid saline matters usually existing in the stomach of animals. Philos Trans R Soc Lond 1824;1:45-9.
7. Beaumont W. Further experiments on the case of Alexis St Martin who was wounded in the stomach by a load of buckshot, detailed in the Recorder for 1825. Med Recorder 1826;9:94-7.
8. Dale HH Adventures in physiology. London: Pergamon Press, 1953.
9. Popielski L. β-imidazolylathyamin ind die organextracte erster teil. Pflugers Arch 1920;178:214-36.
10. Bayliss W, Starling E. Preliminary communication on the causation of the so called "peripheral reflex secretion" of the pancreas. Lancet 1902;2:810-13.
11. Edkins J. The chemical mechanism of gastric secretion. J Physio Lon, 1906:133-44.
12. 2-receptors. Nature 1972;236:385-90.
13. Marshall BJ, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;321:1273-5.
14. Jaworski W. Podręcznik chorób żołądka (Handbook of Gastric Diseases). Wydawnictwa Dziet Lekarskich Polskich 1899;30-47.
15. Metchnikoff I. Immunity in infective diseases. Translated by F.G. Binnie. Cambridge University Press (1905). ISBN 0548-64719-4.
16. Pel PK De ziekten van den maag. ('Diseases of the stomach'). Amsterdam: De Erven Bohn (Publisher), 1899.
17. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21-34.
18. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans-potential application in the treatment of obesity. Peptides 2011;32:2290-4.
19. Lembo A, Camilleri M, McCallum RW, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146(Suppl. 1):S158-9.
20. Dockray GJ, Varro A, Dimaline R, et al. The gastrins: their production and biological activities. Ann Rev Physiol 2001;63:119-39.
21. Dimaline R, Varro A. Novel roles of gastrin. J Physiol 2014;592:2951-8.
22. Bartfeld S, Bayram T, van de Wetering M, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 2015;148:126-36.
23. Varro A, Kenny S, Hemers E, et al. Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol 2007;292:G1133-40.
24. Bodger K, Ahmed S, Pazmany L, et al. Altered gastric corpus expression of tissue inhibitors of metalloproteinases in human and murine Helicobacter infection. J Clin Pathol 2008;61:72-8.
25. Norsett KG, Steele I, Duval C, et al. Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011;301:G446-53.
26. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:605-12.
27. Murugesan SV, Varro A, Pritchard DM. Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009;29:1055-68.
28. Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140:1444-53.
29. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118:36-47.
30. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in NS-GAS mice is gender specific. Cancer Res 2003;63:942-50.
31. Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011;140:210-20.
32. Hayakawa Y, Jin G, Wang H, et al. CCK2R identifies and regulates gastric antral stem cell states and carcinogenesis. Gut 2015;64:544-53.
33. Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 2009;15:1-16.
34. McNicholl AG, Forne M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European J Gastroenterol Hepatol 2014;26:941-8.
35. Erratum in: Eur J Gastroenterol Hepatol. 2015;27:113.
36. Higham AD, Dimaline R, Varro A, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998;114:817-22.
37. Moore AR, Boyce M, Steele IA, et al. Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis. PloS ONE 2013;8:e76462.
38. Fossmark R, Sordal O, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012;36:1067-75.
39. Farré R, Tack J. Food and symptom generation in functional gastrointestinal disorders: physiological aspects. Am J Gastroenterol 2013;108:698-706.
40. Powley TL, Phillips RJ. Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav 2004;82:69-74.
41. Goo T, Akiba Y, Kaunitz JD. Mechanisms of intragastric pH sensing. Curr Gastroenterol Rep 2010;12:465-70.
42. Tack J, Deloose E, Ang D, et al. Motilin induced gastric contractions signal hunger in man. Gut Published Online First: 24 Dec 2014. doi:10.1136/gutjnl-2014-308472
43. Deloose E, Vos R, Depoortere I, et al. Endogenous motilin, but not ghrelin plasma levels fluctuate in accordance with gastric phase III activity of the migrating motor complex in man. Neurogastroenterol Motil 2015;27:63-71.
44. Deloose E, Janssen P, Depoortere I, et al. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol 2012;9:271-85.
45. Vanden Berghe P, Janssen P, Kindt S, et al. Contribution of different triggers to the gastric accommodation reflex in humans. Am J Physiol Gastrointest Liver Physiol 2009;297:G902-6.
46. Janssen P, Verschueren S, Giao Ly H, et al. Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil 2011;23:316-22, e153-4.
47. Janssen P, Vanden Berghe P, Verschueren S, et al. Review article: the role of gastric motility in the control of food intake. Aliment Pharmacol Ther 2011;33:880-94.
48. Janssen P, Verschueren S, Tack J. Intragastric pressure as a determinant of food intake. Neurogastroenterol Motil 2012;24:612-e268.
49. Janssen P, Pottel H, Vos R, et al. Endogenously released opioids mediate meal-induced gastric relaxation via peripheral mu-opioid receptors. Aliment Pharmacol Ther 2011;33:607-14.
50. Rotondo A, Janssen P, Mulè F, et al. Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion. Int J Obes (Lond) 2013;37:593-8.
51. Papathanasopoulos A, Rotondo A, Janssen P, et al. Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health. Neurogastroenterol Motil 2013;25:e263-71.
52. Parkman HP, Yates K, Hasler WL, et al, National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011;140:101-15.
53. Parkman HP, Yates K, Hasler WL, et al, National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011;9:1056-64.
54. Janssen P, Scott Harris M, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013;108:1382-91.
55. Karamanolis G, Caenepeel P, Arts J, et al. Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut 2007;56:29-36.
56. Kumar A, Attaluri A, Hashmi S, et al. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 1008;20:635-42.
57. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310:2640-9.
58. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-91.
59. Vandenberghe J, Vos R, Persoons P, et al. Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? Gut 2005;54:914-19.
60. Phillips RJ, Powley TL. Tension and stretch receptors in gastrointestinal smooth muscle: re-evaluating vagal mechanoreceptor electrophysiology. Brain Res Rev 2000;34:1-26.
61. Distrutti E, Azpiroz F, Soldevilla A, et al. Gastric wall tension determines perception of gastric distension. Gastroenterology 1999;116:1035-42.
62. Piessevaux H, Tack J, Wilmer A, et al. Perception of changes in wall tension of the proximal stomach in humans. Gut 2001;49:203-8.
63. Tack J, Coulie B, Wilmer A, et al. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000;46:468-73.
64. Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28:1326-33.
65. Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-45.
66. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-87.
67. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-5, e250-1.
68. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-8.
69. Pauwels A, Altan E, Tack J. The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2014;26:581-8.
70. Janssen S, Laermans J, Verhulst PJ, et al. Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc Natl Acad Sci USA 2011;108:2094-9.
71. Verschueren S, Deloose E, Janssen S, et al. The Effect of a bitter receptor agonist on food intake and satiation in healthy volunteers. Gastroenterology 2012;142: S-294.
72. Boesmans W, Owsianik G, Tack J, et al. TRP channels in neuro-gastroenterology: opportunities for therapeutic intervention. Br J Pharmacol 2011;162:18-37.
73. Berthoud H-R. The vagus nerve, food intake and obesity. Regul Peptides 2008;149:15-25.
74. Camilleri M, Toouli J, Herrera M, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery 2008;143:723-31.
75. Browning KN, Fortna SR, Hajnal A. Roux-en-Y gastric bypass reverses the effects of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones. J Physiol 2013;591:2357-72.
76. Phillips RJ, Powley TL. Gastric volume rather than nutrient content inhibits food intake. Am J Physiol 1996;271:R766-9.
77. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
78. Delhanty P, Neggers S, van der Lely A. Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin. Eur J Endocrinol 2012;167:601-8.
79. Acosta A, Abu Dayyeh BK, Port JD, et al. Recent Advances in Clinical Practice: Challenges and opportunities in management of obesity. Gut 2014;63:687-95.
80. Park M-I, Camilleri M. Gastric motor and sensory functions in obesity. Obesity Res 2005;13:491-500.
81. Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology 2015;148:537-46.
82. Vazquez Roque MI, Camilleri M, Stephens DA, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight and obese people. Gastroenterology 2006;131:1717-24.
83. Delgado-Aros S, Cremonini F, Castillo EJ, et al. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology 2004;126:432-40.
84. Delgado-Aros S, Camilleri M, Castillo EJ, et al. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol 2005;3:997-1006.
85. Blundell J, Gillett A. Control of food intake in the obese. Obes Res 2001; 9(Suppl. 4):263S-70S.
86. Smith GP The controls of eating: a shift from nutritional homeostasis to behavioral neuroscience. Nutrition 2000;16:814-20.
87. English P, Ghatei M, Malik IA, et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002;87:2984.
88. Lindgren A, Barkeling B, Hagg A, et al. Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. J Pediatr 2000;137:50-5.
89. Thomsen W, Grottick A, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exper Ther 2008;325:577-87.
90. Hardbower DM, Peek RM Jr, Wilson KT. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol 2014;96:201-12.
91. Mayerle J, den Hoed CM, Schurmann C, et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013;309:1912-20.
92. Rad R, Brenner L, Bauer S, et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006;131:525-37.
93. Harris PR, Wright SW, Serrano C, et al. Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 2008;134:491-9.
94. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011;121:3088-93.
95. Kao JY, Zhang M, Miller MJ, et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 2010;138:1046-54.
96. Das S, Sarkar A, Ryan KA, et al. Brain angiogenesis inhibitor 1 is expressed by gastric phagocytes during infection with Helicobacter pylori and mediates the recognition and engulfment of human apoptotic gastric epithelial cells. FASEB J 2014;28:2214-24.
97. Barrozo RM, Cooke CL, Hansen LM, et al. Functional plasticity in the type IV secretion system of Helicobacter pylori. PLoS Pathog 2013;9:e1003189.
98. Persson C, Canedo P, Machado JC, et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am J Epidemiol 2011;173:259-70.
99. Ericksen RE, Rose S, Westphalen CB, et al. Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut 2014;63:385-94.
100. Li X-X, Wong GL-H, To K-F, et al. Bacterial Microbiota Profiling in Gastritis without Helicobacter pylori Infection or Non-Steroidal Anti-Inflammatory Drug Use. PLoS ONE 2009;4:e7985.
101. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006;103:732-7.
102. Andersson AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE 2008;3:e2836.
103. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastroint Surg 2000;4:50-4.
104. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86:174-93.
105. Korecka A, Arulampalam V. The gut microbiome: scourge, sentinel or spectator? J Oral Microbiol 2012;4.
106. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688-93.
107. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxico 2005;96:94-102.
108. Manson JM, Rauch M, Gilmore MS. The commensal microbiology of the gastrointestinal tract. Adv Exp Med Biol 2008;635:15-28.
109. Bhaskar KR, Garik P, Turner BS, et al. Viscous fingering of HCl through gastric mucin. Nature 1992;360:458-61.
110. Corfield AP, Carroll D, Myerscough N, et al. Mucins in the gastrointestinal tract in health and disease. Front Biosci 2001;6:D1321-57.
111. Atuma C, Strugala V, Allen A, et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastroint Liver Physiol 2001;280: G922-9.
112. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiol Prevention. Cancer Res 1992;52:6735-40.
113. Lertpiriyapong K, Whary MT, Muthupalani S, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut 2014;63:54-63.
114. Delgado S, Cabrera-Rubio R, Mira A, et al. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol 2013;65:763-72.
115. Stearns JC, Lynch MD, Senadheera DB, et al. Bacterial biogeography of the human digestive tract. Scientific Rep 2011;1:170.
116. Monstein HJ, Tiveljung A, Kraft CH, et al. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol 2000;49:817-22.
117. Dicksved J, Lindberg M, Rosenquist M, et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol 2009;58(Pt 4):509-16.
118. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J 2011;5:574-9.
119. Stockbrugger RW Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl 1985;111:7-16.
120. Svendsen JH, Dahl C, Svendsen LB, et al. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol 1986;21:16-20.
121. Ahn JS, Eom CS, Jeon CY, et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol 2013;19:2560-8.
122. Tannenbaum SR, Wishnok JS, Leaf CD. Inhibition of nitrosamine formation by ascorbic acid. Am J Clin Nutr 1991;53(1 Suppl):247S-50S.
123. Gramlich G, Zhang J, Nau WM. Increased antioxidant reactivity of vitamin C at low pH in model membranes. J Am Chem Soc 2002;124:11252-3.
124. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10.
125. Yeomans ND, Brimblecombe RW, Elder J, et al. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995;40(2 Suppl):81S-95S.
126. Sanduleanu S, Jonkers D, de Bruine A, et al. Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. Dig Liv Dis 2001;33:707-19.
127. Osaki T, Mabe K, Hanawa T, et al. Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J Med Microbiol 2008;57(Pt 7):814-19.
128. Pei Z, Bini EJ, Yang L, et al. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci USA 2004;101:4250-5.
129. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
130. Pizzi M, Saraggi D, Fassan M, et al. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis 2014;32: 265-74.
131. Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis 2011;43(SUPPL. 4):S373-84.
132. Graham DY History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014;20:5191-204.
133. Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013;27:205-23.
134. Rugge M, Fassan M, Graham DY. Clinical guidelines: Secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol 2012;9:128-9.
135. Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Dig Liver Dis 2008;40:490-6.
136. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-76.
137. Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol 2013;27:159-69.
138. Correa P. Gastric cancer: overview. Gastroenterol Clin North America 2013;42:211-17.
139. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am Journal Surg Pathol 1996;20:1161-81.
140. Price AB The Sydney System: histological division. J Gastroenterol Hepatol 1991;6:209-22.
141. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94.
142. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005;36:228-33.
143. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-8.
144. Rugge M, Genta RM, Group O. Staging gastritis: an international proposal. Gastroenterology 2005;129:1807-8.
145. Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-11.
146. Daugule I, Sudraba A, Chiu HM, et al. Gastric plasma biomarkers and Operative Link for Gastritis Assessment gastritis stage. European J Gastroenterol Hepatol 2011;23:302-7.
147. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17:4596-601.
148. den Hoed CM, Holster IL, Capelle LG, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013;45: 249-56.
149. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-6.
150. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.
151. Sugano K, Tack J, Kuipers EJ, et al. The Kyoto Global Consensus Report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
152. Sonnenberg A. Historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther 2013;36:329-42.
153. Sonnenberg A. Smoking and mortality from peptic ulcer in the United Kingdom. Gut 1986;27:1369-72.
154. Sonnenberg A. Dietary salt and gastric ulcer. Gut 1986;27:1138-42.
155. Sonnenberg A. Differences in the birth-cohort patterns of gastric cancer and peptic ulcer. Gut 2010;59:736-43.
156. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43:327-33.
157. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34:1269-81.
158. Cucino C, Sonnenberg A. The long-term time trends of ulcerative colitis and peptic ulcer are interrelated. Am J Gastroenterol 2002;97:2657-62.
159. Sonnenberg A. Effects of birth cohort on long-term trends in mortality from colorectal cancer. Clin Gastroenterol Hepatol 2012;10:1389-94.
160. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013;108:208-15.
161. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-28.
162. Hawkey CJ Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
163. Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010;77:6-12.
164. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014;147: 784-792.e9.
165. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
166. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
167. Ye X, Fu J, Yang Y, et al. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS ONE 2013;8:e71522.
168. Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a metaanalysis. Br J Cancer 2009;100:551-7.
169. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
170. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus Metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med, 1993;328:308-12.
171. Gillen D, El-Omar EM, Wirz A, et al. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy volunteers. Gastroenterology 1998;114:50-7.
172. Malfertheiner P, Chan FKL, McColl KEL Peptic ulcer disease. Lancet 2009;374:1449-61.
173. Axon ATR, O'Morain CA, Bardhan KD, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 1997;314:565-74.
174. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatoey drug-related injury to the gastrointestinal tract: Clinical Picture, Pathogenesis, and Prevention. Gastroenterol Clin North Am 2010;39:433-64.
175. McColl KEL. Helicobacter pylori negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am 2009;38:353-61.
176. Gururatsakul M, Holloway RH, Talley NJ, et al. Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. J Gastroenterol Hepatol 2010;25:1162-9.
177. Matthewson K, Pugh S, Northfield TC. Which peptic ulcer patients bleed? Gut 1988;29:70-4.
178. Wilcox CM, Clark WS. Features associated with painless peptic ulcer bleeding. Am J Gastroenterol 1997;92:1289-92.
179. Lu CL, Chang SS, Wang SS, et al. Silent peptic ulcer disease, frequency, factors leading to "silence" and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004;60:34-8.
180. Buckley MJM, O'Shea J, Grace A, et al. A community-based study of the epidemiology of Helicobacter pylori infection and associated asymptomatic gastroduodenal pathology. Eur J Gastroenterol Hepatol 1998;10:375-9.
181. El-Omar E, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: Critical role of H. pylori. Gastroenterology 2000;118:22-30.
182. Vaira D, Miglioli M, Mule P, et al. Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut 1994;35:309-12.
183. McColl KEL, El-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998;42:618-22.
184. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:iii-iv, 1-164.
185. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008;6:418-25.
186. Sung JJY, Chan FK, Ching JY, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut 2011;60:1170-7.
187. Nice Guideline on Acute Upper Gastrointestinal Bleeding. 2014 GC141. http://www.nice.org.uk/guidance/cg141/chapter/1-recommendations
188. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on management of patients with Nonvariceal upper Gastrointestinal Bleeding. Ann Intern Med 2010;152:101-13.
189. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
190. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
191. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 100B. 2012:385-435.
192. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-60.
193. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk of gastric cancer? Ann Intern Med 2009;151:121-8.
194. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ 2014;348:g3174.
195. Fukase K, Kato M, Kikuchi S, et al, for the Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
196. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39-46.
197. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12:793-800.
198. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014;109:60-7.
199. Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J Gastroenterol 2001;36:445-56.
200. Sugano K. Premalignant conditions of gastric cancer. J Gastroenterol Hepatol 2013;28:906-11.
201. Vermeer IT, Engels LG, Pachen DM, et al. Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole. Gastroenterology 2001;121:517-25.
202. Wu MS, Shun CT, Wu CC, et al. Epstein-Barr virus-associated gastric carcinomas: Relation to H. pylori infection and genetic alterations. Gastroenterology 2000;118:1031-8.
203. Sugano K, Osawa H, Satoh K. Clinical management of Helicobacter pylori - the Japanese perspective. Dig Dis 2014;32:281-9.
204. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-82.
205. Suzuki H, Gotoda T, Sasako M, et al. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2006;9:315-19.
206. Ezoe Y, Muto M, Uedo N, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011;141:2017-25.
207. Osawa H, Yamamoto H, Miura Y, et al. Diagnosis of depressed-type early gastric cancer using small-caliber endoscopy with flexible spectral imaging color enhancement. Dig Endosc 2012;24:231-6.
208. Osawa H, Yamamoto H, Miura Y, et al. Blue-laser imaging provides excellent endoscopic images of upper gastrointestinal lesions. Video J Encyclopedia GI endoscopy 2014;1:607-10.
209. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
210. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-47.
211. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-8.
212. Capelle LG, de Vries AC, Haringsma J, et al. Serum levels of leptin as marker for patients at high risk of gastric cancer. Helicobacter 2009;14:596-604.
213. Aida K, Yoshikawa H, Mochizuki C, et al. Clinicopathological features of gastric cancer detected by endoscopy as part of annual health checkup. J Gastroenterol Hepatol 2008;23:632-7.
214. Lassen A, Hallas J, de Muckadell OB The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication. Gastroenterology 2005;129:1179-86.
215. Shawihdi M, Thompson E, Kapoor N, et al. Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. Gut 2014;63:250-61.
216. Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. Gut 2011;60:722-37.
217. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
218. Arnold M, Moore SP, Hassler S, et al. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut 2014;63:64-71.
219. Malfertheiner P, Selgrad M. Stomach and Duodenum. Helicobacter pylori. Curr Opin Gastroenterol 2014;30:589-95.
220. Blaser MJ Equilibria of humans and our indigenous microbiota affecting asthma. Proc Am Thorac Soc 2012;9:69-71.
221. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014;11:628-38.
222. Selgrad M, Bornschein J, Kandulski A, et al. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. Int J Cancer 2014;135:1127-31.
223. Schulz C, Schütte K, Malfertheiner P. Does H. pylori eradication therapy benefit patients with hepatic encephalopathy? Systematic review. J Clin Gastroenterol 2014;48:491-9.
224. Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol 2013;27:39-45.